Wir sind mit live! Mehr erfahren

SI-BONE Inc

SIBN

Börsenwert 882 Mio. $

19,68 USD

-0,23

1,16 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

19,77

+0,09

0,46 %

1 Tag

-1,16 %

5 Tage

1,44 %

1 Monat

6,15 %

3 Monate

11,06 %

6 Monate

43,96 %

Seit Jahresbeginn

-0,56 %

1 Jahr

30,33 %

5 Jahre

-9,27 %

10 Jahre

-1,89 %

Profil: SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

Mitarbeiter: 376

Gesundheitswesen Medizintechnik

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 27,3 %

Neutral 63,6 %

Negativ 9,1 %

SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis

FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone

SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis

SI-BONE, Inc. (SIBN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

SI-BONE, Inc. (SIBN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

SI-BONE, Inc. (SIBN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026

SANTA CLARA, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Monday, September 14, 2026, at 8:30 a.m. Pacific Time/ 11:30 a.m. Eastern Time.

SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026

Zacks Investment Research

Si-Bone (SIBN) is a Great Momentum Stock: Should You Buy?

Does Si-Bone (SIBN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Si-Bone (SIBN) is a Great Momentum Stock: Should You Buy?

Zacks Investment Research

Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 25.25%: Here's is How to Trade

The mean of analysts' price targets for Si-Bone (SIBN) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 25.25%: Here's is How to Trade

Zacks Investment Research

Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect?

The consensus price target hints at a 38.6% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect?

SI-BONE, Inc. (SIBN) Q2 2026 Earnings Call Transcript

SI-BONE, Inc. (SIBN) Q2 2026 Earnings Call Transcript

SI-BONE, Inc. (SIBN) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates

Si-Bone (SIBN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.14 per share a year ago.

Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates

SiBone Q2 Earnings Call Highlights

SiBone NASDAQ: SIBN reported second-quarter 2026 revenue growth of 15.2% and narrowed its net loss as procedure volumes increased across its U.S. business and international demand rose for its expanded product portfolio.

SiBone Q2 Earnings Call Highlights

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance

Delivered ~15% WW revenue growth and ~ 178% increase in adjusted EBITDA ~ 19% increase in U.S. physician base

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt